You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

UCB reveals new Bimzelx ‘complete skin clearance’ data

UCB has announced new three-year results from the BE BRIGHT open-label extension study evaluating the long-term safety, tolerability and efficacy of Bimzelx – also known bimekizumab – in adults with moderate to severe plaque psoriasis.